论文部分内容阅读
目的:为探讨罗格列酮对糖耐量减低(IGT)的干预治疗对代谢性指标的治疗价值。方法:通过对57例IGT患者为期6个月的小剂量罗格列酮临床治疗观察,体重指数(BMI)、腹围/臂围、血尿酸、血脂、尿微量白蛋白(尿A/C)、肝肾功、血压等项目进行监测。结果:服药6个月、24个月后复查该57例患者治疗前后空腹及餐后血糖,均恢复正常;高胰岛素状态得到好转并接近正常;腹围/臂围比下降;甘油三脂大致恢复正常;脂肪肝好转、肝功、肾功正常;血压控制较好。尿微量白蛋白(尿A/C)较前明显好转,腹围/臂围<0.9。空腹血糖<6.4mmol/L,餐后2小时血糖<5.8±2.2mmol/L。在服药期间患者无明显不良反应,无低血糖发生。结论:经为期24个月的临床观察表明罗格列酮干预治疗IGT,可达到显著降低糖尿病的代谢性指标。
Objective: To investigate the therapeutic value of rosiglitazone in the treatment of impaired glucose tolerance (IGT) on metabolic parameters. Methods: Fifty-seven patients with IGT were treated with low-dose rosiglitazone for 6 months. Body mass index (BMI), abdominal circumference / arm circumference, serum uric acid, blood lipid, urine microalbuminuria , Liver and kidney function, blood pressure and other items to be monitored. Results: The fasting and postprandial blood glucose of the 57 patients after 6 months and 24 months’ retesting returned to normal, the state of hyperinsulin improved and approached to normal, the ratio of abdominal circumference / arm circumference decreased, and the triglyceride returned to normal Normal; fatty liver improved, liver function, normal kidney function; blood pressure control is better. Microalbuminuria (urinary A / C) was significantly improved compared with the previous, abdominal circumference / arm circumference <0.9. Fasting blood glucose <6.4mmol / L, 2 hours postprandial blood glucose <5.8 ± 2.2mmol / L. No significant adverse reactions during the medication, no hypoglycemia. Conclusion: The 24-month clinical observation shows that rosiglitazone can significantly reduce the metabolic index of diabetes mellitus after intervention with IGT.